Opthea Past Earnings Performance
Past criteria checks 0/6
Opthea's earnings have been declining at an average annual rate of -50.4%, while the Biotechs industry saw earnings growing at 13.2% annually. Revenues have been growing at an average rate of 17.5% per year.
Key information
-50.4%
Earnings growth rate
-37.4%
EPS growth rate
| Biotechs Industry Growth | 9.6% |
| Revenue growth rate | 17.5% |
| Return on equity | n/a |
| Net Margin | -84,107.1% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Is Opthea (ASX:OPT) In A Good Position To Invest In Growth?
Jul 21
Here's Why We're Watching Opthea's (ASX:OPT) Cash Burn Situation
Mar 24We're Hopeful That Opthea (ASX:OPT) Will Use Its Cash Wisely
Dec 09This Is Why Opthea Limited's (ASX:OPT) CEO Compensation Looks Appropriate
Oct 12Here's Why We're Not Too Worried About Opthea's (ASX:OPT) Cash Burn Situation
Aug 24We Think Opthea (ASX:OPT) Can Afford To Drive Business Growth
Mar 01What Type Of Shareholders Make Up Opthea Limited's (ASX:OPT) Share Registry?
Dec 13
Revenue & Expenses Breakdown
How Opthea makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -220 | 16 | 176 |
| 31 Mar 24 | 0 | -191 | 15 | 164 |
| 31 Dec 23 | 0 | -162 | 19 | 145 |
| 30 Sep 23 | 0 | -152 | 24 | 134 |
| 30 Jun 23 | 0 | -143 | 28 | 122 |
| 31 Mar 23 | 0 | -137 | 28 | 115 |
| 31 Dec 22 | 0 | -132 | 27 | 108 |
| 30 Sep 22 | 0 | -113 | 23 | 93 |
| 30 Jun 22 | 0 | -93 | 18 | 79 |
| 31 Mar 22 | 0 | -75 | 17 | 61 |
| 31 Dec 21 | 0 | -57 | 16 | 44 |
| 30 Sep 21 | 0 | -51 | 14 | 35 |
| 30 Jun 21 | 0 | -45 | 13 | 26 |
| 31 Mar 21 | 0 | -39 | 11 | 23 |
| 31 Dec 20 | 0 | -31 | 7 | 19 |
| 30 Sep 20 | 0 | -21 | 6 | 16 |
| 30 Jun 20 | 0 | -11 | 5 | 12 |
| 31 Mar 20 | 0 | -10 | 4 | 12 |
| 31 Dec 19 | 0 | -12 | 4 | 16 |
| 30 Sep 19 | 0 | -13 | 4 | 18 |
| 30 Jun 19 | 0 | -15 | 4 | 22 |
| 31 Mar 19 | 0 | -13 | 3 | 22 |
| 31 Dec 18 | 0 | -12 | 3 | 22 |
| 30 Sep 18 | 0 | -12 | 3 | 20 |
| 30 Jun 18 | 0 | -13 | 3 | 18 |
| 31 Mar 18 | 0 | -12 | 4 | 14 |
| 31 Dec 17 | 0 | -12 | 4 | 10 |
| 30 Sep 17 | 0 | -8 | 4 | 7 |
| 30 Jun 17 | 0 | -5 | 4 | 4 |
| 31 Mar 17 | 0 | -5 | 4 | 4 |
| 31 Dec 16 | 0 | -5 | 3 | 4 |
| 30 Sep 16 | 0 | -5 | 3 | 3 |
| 30 Jun 16 | 0 | -5 | 3 | 3 |
| 31 Mar 16 | 0 | -4 | 3 | 3 |
| 31 Dec 15 | 0 | -3 | 3 | 3 |
| 30 Sep 15 | 0 | -3 | 2 | 3 |
| 30 Jun 15 | 0 | -4 | 3 | 4 |
| 31 Mar 15 | 1 | -4 | 2 | 4 |
| 31 Dec 14 | 1 | -4 | 2 | 4 |
| 30 Sep 14 | 1 | -4 | 3 | 4 |
| 30 Jun 14 | 1 | -4 | 3 | 3 |
| 31 Mar 14 | 1 | -3 | 3 | 3 |
| 31 Dec 13 | 1 | -2 | 3 | 3 |
| 30 Sep 13 | 1 | -3 | 4 | 3 |
Quality Earnings: OPT is currently unprofitable.
Growing Profit Margin: OPT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: OPT is unprofitable, and losses have increased over the past 5 years at a rate of 50.4% per year.
Accelerating Growth: Unable to compare OPT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OPT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).
Return on Equity
High ROE: OPT's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.